Prev Close | 5.11 |
Open | 4.97 |
Day Low/High | 4.92 / 5.14 |
52 Wk Low/High | 3.66 / 7.41 |
Volume | 18.54K |
Prev Close | 5.11 |
Open | 4.97 |
Day Low/High | 4.92 / 5.14 |
52 Wk Low/High | 3.66 / 7.41 |
Volume | 18.54K |
Exchange | NASDAQ |
Shares Outstanding | 13.41B |
Market Cap | 68.53M |
P/E Ratio | N/A |
Div & Yield | N.A. (N.A) |
The Dow Jones Industrial Average's road to 20,000 has another detour as a selloff in crude spooks the energy sector.
Merrimack Pharmaceuticals agreed to sell oncology treatments, including its pancreatic-cancer treatment Onivyde, to French drugmaker Ipsen.
Small-caps could also benefit from abating tax-loss selling.
It was good to stand in for Doug Kass today. Lots of lively conversation this Friday (over 200 comments), most of them around the markets as well....:-). The Daily Diary was certainly more interesting than today's market, which ended mixed as it clo...
The first day of trading in the fourth quarter was rough as stocks declined Monday.
Thermo Fisher is looking bullish, while Blue Buffalo goes the other way.
New drugs give small-cap companies opportunity to expand markets and revenues.
The sector seems to be rebounding after tumbling by more than 40%.
Following Galenica's $1.5 billion bid for Relypsa, investors are beginning to search for the next target.
Let's look at other attractively valued bets in what is at least a slightly overbought market overall.
I continue to like RLYP, TPH and LGIH.
These concerns are well on their way to FDA approval for their first commercialized products in addressable markets.
Pharma and biotech giants now must look to small- and mid-caps to fill out pipelines and bolster growth.
Drug maker Relypsa is poised for a huge upside, despite the current market sentiment.
Drug maker Relypsa is poised for a huge upside, despite the current market sentiment.
And yet, Endocyte has a deep pipeline.
My 4-Tier approach to deploying new capital in the sector.
Each of these small-caps delivered good news recently, only to have their stocks decline.
Each of these small-caps delivered good news recently, only to have their stocks decline.
The sector saw solid performance this week as the biotech juggernaut mounted a long-overdue rally.
The sector saw solid performance this week as the biotech juggernaut mounted a long-overdue rally.
Here are some mid-cap names with solid upside potential.
A so-called "pyramid strategy" can help you enter the depressed sector.
Biotech's pipeline includes a cancer drug that's close to approval.
Maybe earnings reports will rattle the market's cage.
The fear in this market is about being left out.
Allocate to numerous attractive, but speculative positions.
Merrimack and Threshold Pharmaceuticals will soon announce catalysts to propel their stocks, says Rob Goldman of Goldman Small Cap Research.